Skip to content

MOVIN Pilot Randomized Controlled Trial

Reproductive Mental Health of Ontario Virtual Intervention Network (MOVIN): A Pilot Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04680585
Acronym
MOVIN
Enrollment
101
Registered
2020-12-23
Start date
2021-04-12
Completion date
2022-12-30
Last updated
2025-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Postpartum

Brief summary

Despite available treatments for perinatal mood disorders, only 20% of affected women receive treatment that results in remission of symptoms. In order to address gaps in equitable access to treatment the investigators developed the Reproductive Mental health of Ontario Virtual Intervention Network (MOVIN), a virtual collaborative care platform to optimize access for pregnant and postpartum people in Ontario. MOVIN combines collaborative and stepped-care approaches to treatment of perinatal depression and anxiety. The overall objective of this pilot randomized controlled trial (RCT) is to determine the feasibility of implementing a protocol for studying MOVIN for pregnant and postpartum individuals with significant symptoms of depression and anxiety (EPDS \> 12) in order to inform the conduct of a larger scale evaluation. O will be randomized to either the MOVIN or control condition and will be asked to complete follow-up assessments 12- and 24-weeks post-randomization. Participants in the MOVIN arm will receive access to the MOVIN platform which includes a care coordinator to help them navigate various virtual treatments. Participants in the control condition will receive a resource list and will navigate the various options on their own.

Detailed description

People with scores above 12 on the EPDS have a 10 times greater likelihood of having a diagnosis of depression than those with scores with 12 or less, so this is an appropriate cut-off. The primary endpoint is at 12 weeks post-randomization and the secondary endpoint is at 24 weeks post-randomization. Randomization will be performed as block randomization (varying block sizes) with a 1:1 allocation and will be stratified based on EPDS score (13-19 vs. 20 or greater). Participants who score 12 or less on the EPDS in their initial self-referral screen will be informed that they are not at high risk for having depressive or anxiety disorder and the current time, and can re-screen as needed. Participants whose score is in the 9-12 range (i.e. those who are not likely to be experiencing a depressive or anxiety disorder requiring mental health treatment, but might benefit from additional support) will receive an automated message that communicates their score and the acknowledgment of their possible need for support, and provides a list of resources in Ontario that may be helpful for them. These participants will be invited to re-screen at any time into the study, and will be asked permission to be re-contacted in future to determine which supports they used, if any.

Interventions

OTHEREnhanced Usual Care

A standardized handout with information on what treatment options might be useful to start with based on EPDS score and stage of pregnancy or postpartum.

Virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.

Sponsors

Women's College Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Residents of Ontario at least 18 years of age 2. Currently pregnant or mother\* of a live infant 0-12 months of age living at the same residence \*through natural birth, adoption or surrogacy, including cis women, non-binary and transgender people in all their diversity 3. EPDS \> 12 4. Registered with a primary care provider

Exclusion criteria

1. Experiencing active suicidal ideation (MINI International Neuropsychiatric Interview) 2. Active substance use disorder (GAIN-SS), current mania or psychosis (MINI Neuropsychiatric Interview) 3. Unable to access the internet or a device that can support the MOVIN platform 4. Unable to participate in English 5. Unable to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of the trial protocol: Acceptability12 weeks post randomizationMeasures of acceptability include participants' overall experience and satisfaction with and acceptance of the MOVIN platform and the care coordinator, the care coordinator's assessment of the MOVIN platform and its impact on patient care, and primary care providers' assessment of MOVIN's impact on patient care.
Feasibility of the trial protocol: Compliance12 weeks post randomizationMeasures of compliance include rate of completion of MOVIN-specific activities, rate of completion of suggested interventions, and rate of resource use.
Feasibility of the trial protocol: Recruitment12 weeks post randomizationMeasures of recruitment and retention include rate of recruitment, reason for non-participation and rate of completion of follow-up measures.

Secondary

MeasureTime frameDescription
Feasibility of the trial protocol: Compliance24 weeks post randomizationMeasures of compliance include rate of completion of MOVIN-specific activities, rate of completion of suggested interventions, and rate of resource use.
Maternal clinical outcomes - depression symptoms12 and 24 weeks post randomizationDepressive symptoms will be measured using the Edinburgh Postnatal Depressive Scale (EPDS), a self-report scale that has been validated for use in pregnancy and postpartum. EPDS scores range from 0 to 30. EPDS scores \>12 are predictive of a diagnosis of depression, with higher scores indicating more severe symptoms.
Maternal clinical outcomes - anxiety symptoms12 and 24 weeks post randomizationAnxiety symptoms will be measured using the General Anxiety Disorder-7 (GAD-7) scale, which is a self-report scale with good discriminate validity in perinatal populations. GAD-7 scores range from 0 to 21, with higher scores indicating more severe symptoms.
Maternal clinical outcomes - quality of life12 and 24 weeks post randomizationQuality of life will be measured using the 5 Level-5 Dimension EuroQol 5 (EQ-5D-5L) which is a multi-attribute utility instrument for measuring quality-adjusted life year (QALY), a preference-based utility measure of health-related quality of life as perceived by the patient. It can define 3125 different health states ranging from 11111 (full health) to 55555 (worst health).
Health service use: participant time12 and 24 weeks post randomizationMeasured by participant self-report of activities related to attending appointments and obtaining services.
Health service use: health system costs12 and 24 weeks post randomizationCalculated from participant self-report of medical costs such as hospitalizations, visits with health professionals and medications.
Care coordinator time12 and 24 weeks post randomizationCare coordinator time per participant will be measured as the time spent per participant on the MOVIN platform, time spent on phone assessments and other related activities.
Care coordinator cost12 and 24 weeks post randomizationCare coordinator cost per participant will be measured as the cost per participant on the MOVIN platform, on phone assessments and other related activities.
Dyadic relationship12 and 24 weeks post randomizationThe Dyadic Adjustment Scale (DAS) is a self-report measure of relationship adjustment with an intimate partner and will be used to measure relationship distress. The first 15 items of the 32-item measure will be used to assess dyadic consensus. Scores range fro 0 to 75. Higher scores indicate a higher degree of dyadic consensus.
Maternal child relationship12 and 24 weeks post randomizationAll participants who are postpartum at any time point will complete Parenting Stress Index short form (PSI-SF) to measure parenting stress. This is a 36-item measure consisting of 3 sub-scales: parental distress, dysfunction in the parent-child relations and difficult child. Scores range from 36 to 180. Higher scores indicate higher levels of parenting stress.
Infant temperamentBaseline, 12 and 24 weeks post randomizationInfant temperament will be measured using the Infant Characteristics Questionnaire (ICQ), an instrument that assesses parental perceptions of difficult infant temperament. Scores range from 28 to 196. Higher scores indicate a higher level of parental perceptions of difficult infant temperament.
Health service use: participant cost12 and 24 weeks post randomizationMeasured by participant self-report of costs related to attending appointments and obtaining services.
Feasibility of the trial protocol: Recruitment24 weeks post randomizationMeasures of recruitment and retention include rate of recruitment, reason for non-participation and rate of completion of follow-up measures.
Feasibility of the trial protocol: Acceptability24 weeks post randomizationMeasures of acceptability include participants' overall experience and satisfaction with and acceptance of the MOVIN platform and the care coordinator, the care coordinator's assessment of the MOVIN platform and its impact on patient care, and primary care providers' assessment of MOVIN's impact on patient care.

Other

MeasureTime frameDescription
Co-variatesBaselineWe will collect sociodemographic, obstetrical and psychiatric history data. We will also conduct a diagnostic phone interview using the MINI International Neuropsychiatric Interview for major depressive disorder, obsessive-compulsive disorder, panic disorder, agoraphobia, social anxiety disorder, generalized anxiety disorder, alcohol and substance abuse, past (hypo)mania and psychosis, and post-traumatic stress disorder.
Neonatal birth outcomesBaseline, 12 and 24 weeks post randomizationSelf-reported neonatal birth outcomes including medical conditions and complications, if applicable.
Maternal birth outcomesBaseline, 12 and 24 weeks post randomizationSelf-reported pregnancy and birth complications, if applicable.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026